These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9630998)

  • 21. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA.
    Watson SA; Morris TM; Collins HM; Bawden LJ; Hawkins K; Bone EA
    Br J Cancer; 1999 Sep; 81(1):19-23. PubMed ID: 10487607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymidylate synthase inhibitors.
    Ismail AS; Grem JL
    Cancer Chemother Biol Response Modif; 2001; 19():1-19. PubMed ID: 11686010
    [No Abstract]   [Full Text] [Related]  

  • 24. Epigenetic cancer therapies emerge out of the lab into the limelight.
    Wolfson W
    Chem Biol; 2013 Apr; 20(4):455-6. PubMed ID: 23601631
    [No Abstract]   [Full Text] [Related]  

  • 25. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
    Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aurora kinases dawn as cancer drug targets.
    Sausville EA
    Nat Med; 2004 Mar; 10(3):234-5. PubMed ID: 14991042
    [No Abstract]   [Full Text] [Related]  

  • 27. Tumour marker levels during marimastat therapy.
    Gore M; A'Hern R; Stankiewicz M; Slevin M
    Lancet; 1996 Jul; 348(9022):263-4. PubMed ID: 8684209
    [No Abstract]   [Full Text] [Related]  

  • 28. [Progress in diagnosis and treatment of lung cancer].
    Fukuoka M
    Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():15-22. PubMed ID: 11989256
    [No Abstract]   [Full Text] [Related]  

  • 29. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor.
    Hutchinson JW; Tierney GM; Parsons SL; Davis TR
    J Bone Joint Surg Br; 1998 Sep; 80(5):907-8. PubMed ID: 9768907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):803-21. PubMed ID: 15485315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteinase inhibition in invasive cancer therapy: four control levels of matrix degradation.
    Opdenakker G; Paemen L; Norga K; Masure S
    Int J Cancer; 1997 Mar; 70(5):628-30. PubMed ID: 9052766
    [No Abstract]   [Full Text] [Related]  

  • 32. New targets for cancer chemotherapy.
    Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA
    Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208
    [No Abstract]   [Full Text] [Related]  

  • 33. Marimastat inhibits neointimal thickening in a model of human arterial intimal hyperplasia.
    Peterson M; Porter KE; Loftus IM; Thompson MM; London NJ
    Eur J Vasc Endovasc Surg; 2000 May; 19(5):461-7. PubMed ID: 10828225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antitumor effect of a matrix metalloproteinase inhibitor, TA-2516 (Marimastat), on a nude mouse model of intraperitoneal seeding of stomach cancer].
    Kimata D; Otani Y; Kubota T; Igarashi N; Yokoyama T; Wada N; Kumai K; Okada Y; Kameyama K; Kitajima M
    Nihon Geka Gakkai Zasshi; 1999 May; 100(5):363. PubMed ID: 10475795
    [No Abstract]   [Full Text] [Related]  

  • 35. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
    Grant S
    Leukemia; 2004 Dec; 18(12):1931-3. PubMed ID: 15496978
    [No Abstract]   [Full Text] [Related]  

  • 36. Issues and progress with protein kinase inhibitors for cancer treatment.
    Dancey J; Sausville EA
    Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topoisomerase II inhibitors.
    Clapp JM; Hande KR
    Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
    [No Abstract]   [Full Text] [Related]  

  • 38. New targets for cancer chemotherapy.
    Arbuck SG; Dancey J; Pluda JM; Grochow L; Murgo AJ; Ivy P; Wright J; Blaylock B; Via LE; Sausville EA
    Cancer Chemother Biol Response Modif; 2001; 19():237-88. PubMed ID: 11686017
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic angiogenesis inhibitors in the treatment of cancer.
    Hidalgo M; Pierson AS; Holden SN; Bergen M; Eckhardt SG
    Adv Intern Med; 2001; 47():159-90. PubMed ID: 11795074
    [No Abstract]   [Full Text] [Related]  

  • 40. Preclinical and clinical studies of MMP inhibitors in cancer.
    Drummond AH; Beckett P; Brown PD; Bone EA; Davidson AH; Galloway WA; Gearing AJ; Huxley P; Laber D; McCourt M; Whittaker M; Wood LM; Wright A
    Ann N Y Acad Sci; 1999 Jun; 878():228-35. PubMed ID: 10415734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.